The Juno Board of Directors is comprised of industry leaders with an outstanding track record of navigating novel science and building enduring companies.

Hal Barron

Director

Hal Barron is President, Research and Development at Calico, a Google-back biotechnology company focused on the aging process.

Bio

Hal V. Barron is President, Research and Development, at Calico, a Google-back biotechnology company focused on the aging process. Dr. Barron was most recently Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Hoffmann-La Roche. Dr. Barron joined Genentech in 1996 as a clinical scientist. During the next several years, he held positions of increasing responsibility and leadership within cardiovascular research and specialty therapeutics. In 2002, Dr. Barron was promoted to Vice President of Medical Affairs. In 2003, he became the Senior Vice President of Development and in 2004 he was appointed Chief Medical Officer. In 2009, he was appointed Executive Vice President. Dr. Barron previously served as a director and member of the compensation committee of Alexza Pharmaceuticals Inc., a public pharmaceutical company, from December 2007 to May 2013. Prior to joining Genentech, Dr. Barron received his B.S. in Physics from Washington University in St. Louis, his medical degree from Yale University, and completed his training in medicine and cardiology at the University of California, San Francisco. Dr. Barron’s academic positions include Associate Adjunct Professor at the University of California, San Francisco. He has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.

Hans Bishop

CEO & President

Hans E. Bishop is one of our co-founders and has served as our Chief Executive Officer and a member of our board of directors since September 2013.

Bio


Hans E. Bishop is one of our co-founders and has served as our Chief Executive Officer and a member of our Board of Directors since September 2013. Mr. Bishop has also served as a member of the Board of Directors of Avanir Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, since May 2012. Mr. Bishop previously served as Chairman of the Board of Genesis Biopharma, Inc., a biotechnology company, from January 2012 until November 2012. From February 2012 until October 2012, Mr. Bishop was the Chief Operating Officer of PhotoThera, Inc., a late-stage medical device company owned by Warburg Pincus, and he continued working with Warburg Pincus as an Executive in Residence until October 2013. Mr. Bishop previously served as Executive Vice President and Chief Operating Officer at Dendreon Corporation, a cancer cell therapy company, from January 2010 to September 2011.
Mr. Bishop has also served as the President of the Specialty Medicine Business at Bayer Healthcare Pharmaceuticals, Inc. from December 2006 to January 2010, where he was responsible for a diverse portfolio of neurology, oncology, and hematology products. Mr. Bishop was employed by Chiron Corporation as Senior Vice President of Global Commercial Operations until its sale to Novartis Corporation. Mr. Bishop received a B.Sc. in Chemistry from Brunel University in London.

Thomas Daniel

Director

Thomas Daniel is Chairman of Celgene Research at Celgene Corporation.

Bio


Thomas O. Daniel has been Chairman of Celgene Research at Celgene Corporation since January 2016. Dr. Daniel was previously Celgene’s President of Research and Early Development from December 2006 to January 2016 and served as Celgene Corporation’s Executive Vice President and President of Research and Early Development from February 2012 until July 2014. Prior to joining Celgene, Dr. Daniel served as the Chief Scientific Officer and director at Ambrx Inc., a biotechnology company focused on discovering and developing protein-based therapeutics. Prior to Ambrx, Dr. Daniel served as Vice President of Research at Amgen Inc., where he was research site head of Amgen Washington and therapeutic area head of inflammation. Prior to Amgen’s acquisition of Immunex, Dr. Daniel served as Senior Vice President of Discovery Research at Immunex. Dr. Daniel is a member of the therapeutic advisory board of aTyr Pharma, Inc. and is a director of FerruMax Pharmaceuticals and PharmAkea Therapeutics, privately-held biotechnology companies. Dr. Daniel was also formerly a director of Epizyme, Inc. Dr. Daniel serves as a member of the Biomedical Science Advisory Board of Vanderbilt University Medical Center and the Biomedical Advisory Council of PhRMA. A nephrologist and former academic investigator, Dr. Daniel was previously the K.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University, and Director of the Vanderbilt Center for Vascular Biology. Dr. Daniel received a B.A. from the Southern Methodist University in Texas in 1974 and an M.D. from the University of Texas, Southwestern, in 1978, and completed medical residency at Massachusetts General Hospital.

Anthony Evnin

Director

Anthony Evnin is a Partner of Venrock with significant experience as a director of many other biotechnology companies.

Bio

Anthony Evnin is a Partner of Venrock, a venture capital firm, which he joined in 1974. He is currently a Director, AVEO Pharmaceuticals, Inc., and Infinity Pharmaceuticals, Inc., as well as Constellation Pharmaceuticals, Inc., a private company. Dr. Evnin was formerly a director of many other biotechnology companies. He serves as a Trustee of The Rockefeller University, as a Trustee of The Jackson Laboratory, as a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center, as a Member of the Board of Directors of the New York Genome Center, as a Member of the Board of Directors of the Albert and Mary Lasker Foundation, and as a Trustee Emeritus of Princeton University. Dr. Evnin received a B.A. from Princeton University and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.

Richard Klausner

Director & Co-Founder

Dr. Klausner is founder and Director of GRAIL and Executive Chairman of Wisdo, a third generation internet company.

Bio

Richard Klausner is founder and Director of Juno Therapeutics, founder and Director of GRAIL and Executive Chairman of Wisdo, a third generation internet company. He is the chairman of Mindstrong and a Director of AnchorDx. He is the former Senior Vice President, Chief Medical Officer and Chief Opportunity Officer of Illumina Corporation. He is the former Executive Chairman of Audax Health. He currently Chairs the Grand Challenges in Cancer program of Cancer Research UK. Previously, he has served as managing partner of the Venture Capital firm, The Column Group, and was the Executive Director for Global Health of the Bill and Melinda Gates Foundation. Dr. Klausner was appointed by Presidents Clinton and Bush as the eleventh Director of the U.S. National Cancer Institute between 1995 and 2001. Dr. Klausner served as chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health and Human Development, as well as a past president of the American Society of Clinical Investigation. He has served in senior advisory roles to the U.S., Norwegian, Qatari and Indian governments. He previously chaired the International Advisory Board for Samsung and the Strategic Oversight Council of Sanofi. He currently serves on numerous advisory boards.

Dr. Klausner is well known for his work in cell and molecular biology, immunology and human genetics, and has been the author of more than 300 scientific articles and several books, in addition to receiving numerous awards, honorary degrees and other honors. He has served as an Advisor to the Presidents of the Academies for counter-terrorism, and Liaison to the White House Office of Science & Technology Policy. He oversaw the writing of The National Science Education Standards, the first such standards for U.S. Science Education. He is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.

Robert Nelsen

Director & Co-Founder

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners.

Bio

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing, and development of more than thirty companies. His seed and early-stage investments include Illumina, Alnylam Pharmaceuticals), Juno Therapeutics, Agios Pharmaceuticals, Sage Therapeutics, Ikaria (acquired by Madison Dearborn), Kythera Biopharmaceuticals, Aviron (acquired by Medimmune), Sapphire Energy, NetBot (acquired by Excite), R2 Technology (acquired by Hologic), XenoPort, Caliper Life Sciences (acquired by PerkinElmer), Bluebird Bio, Trubion Pharmaceuticals (acquired by Emergent BioSolutions), Adolor (acquired by Cubist), deCODE Genetics (acquired by Amgen), Array BioPharma, Nanosys, GenVec, IDUN Pharmaceuticals (acquired by Pfizer), Genomica (acquired by Exelixis), Classmates.com (acquired by United Online), Nura (acquired by Omeros), Receptos, Kilimanjaro Energy, Hua Medicine, VLST; Ensemble Therapeutics, Accelerator, Theraclone Sciences, Fate Therapeutics, NextCODE Health, Bellerophon Therapeutics, Syros Pharmaceuticals, and Everyday Learning Corporation (acquired by Tribune Corp.).

Mr. Nelsen is a director of Agios Pharmaceuticals, Juno Therapeutics, Kythera Biopharmaceuticals, Sapphire Energy, Sage Therapeutics, Ensemble Therapeutics, Syros Pharmaceuticals, NextCODE Health, and serves as Chairman of Hua Medicine. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and as a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.

Howard Pien

Chairman & Director

Howard Pien has worked in the pharmaceutical and biotechnology industries for over 30 years.

Bio

Howard Pien has worked in the pharmaceutical and biotechnology industries for over 30 years. In addition to Juno, he currently serves as a director on four boards. He is the Chairman of Indivior PLC, the spinoff of the pharmaceutical division from UK based consumer goods conglomerate Reckitt Benckiser. He is on the boards of Immunogen, Inc., Sage Therapeutics, Inc., and Vanda Pharmaceuticals. Previously, Mr Pien served on the boards of Viropharma, where he was also the Lead Independent Director, and Ikaria, Inc. in addition to board services, Mr Pien is an advisor to Warburg Pincus, a private equity firm. Prior to board services, Mr Pien served as the CEO and Chairman of Medarex, Inc., a biopharmaceutical company, from 06/07 until it was acquired by BMS in 09/09. Mr Pien served as the CEO and Chairman of Chiron Corp., a biotechnology company, from 04/03 until its acquisition by Novartis in 05/06. Prior to joining the biotechnology industry, Howard worked for GSK, Abbott Laboratories, and Merck & Co., Inc. Mr. Pien received a BS from MIT in 1979 and an MBA from Carnegie-Mellon University in 1981. 

Maggie Wilderotter

Director

Maggie Wilderotter has served as a member of our board of directors since November 2014.

Bio

Maggie Wilderotter was Chief Executive Officer of Frontier Communications from November, 2004 to April, 2015, and then Executive Chairman of the company until April, 2016. During her tenure with Frontier, the company grew from a regional telephone company with customer revenues of less than $1 billion to a national broadband, voice and video provider with operations in 29 states and annualized revenues in excess of $10 billion.

Previously, Mrs. Wilderotter was Senior Vice President of Global Business Strategy and ran the Worldwide Public Sector at Microsoft. Before this, she was President and CEO of Wink Communications Inc., Executive Vice President of National Operations for AT&T Wireless Services Inc., Chief Executive Officer of AT&T’s Aviation Communications Division, and a Senior Vice President of McCaw Cellular Communications Inc.

Mrs. Wilderotter serves on the boards of Costco Wholesale Corporation,  Hewlett Packard Enterprise, and Juno Therapeutics, Inc. as well as a number of private and non-profit organizations. Mrs. Wilderotter is also a Senior Advisor to the Blackstone Group.

Mrs. Wilderotter previously served on the President’s National Security Telecommunications Advisory Committee (NSTAC) as both Vice Chairman and Chairman during her 4-year tenure ending in 2014. Mrs. Wilderotter also served until January, 2017 on the President’s special Commission responsible for a recommendation report to the new President of the United States on Enhancing National Cybersecurity.

Mrs. Wilderotter is a member of the Board of Directors of The Conference Board; a member of the Executive Committee of the Catalyst Board of Directors; a member of the Board of Women in America; and a member of the Business Council, WPO; Women Corporate Directors (WCD) and the Committee of 200.

Mrs. Wilderotter holds a bachelor’s degree in economics from the College of the Holy Cross. She has been awarded an Honorary Doctor of Engineering degree from the Stevens Institute of Technology and an Honorary Doctor of Laws degree from the University of Rochester.

Rupert Vessey

Director

Rupert Vessey is EVP and President, Research and Early Development at Celgene.

Bio

Rupert Vessey, MA, BM BCh, FRCP, DPhil, joined Celgene in January 2015 as Senior Vice President, Translational Development.  Before joining Celgene, Dr. Vessey was Senior Vice President of Early Development and Discovery Sciences at Merck. During his ten years with Merck, Dr. Vessey was responsible for numerous drug development programs and served as Senior Vice President, Early Development and Discovery Sciences, Senior Vice President, Respiratory and Immunology Franchise and Vice President, Drug Discovery and Informatics.  Prior to Merck, he spent five years at GlaxoSmithKline in drug discovery, experimental medicine and early clinical development of therapeutics for respiratory and immune diseases.  Dr. Vessey graduated from Oxford University with degrees in Physiological Sciences (MA), Clinical Medicine (BM, BCH) and a DPhil (PhD) in Molecular Immunology.  He is an elected Fellow of the Royal College of Physicians.